CME Presentations

Visual Outcomes in nAMD and DME



  • Durga Borkar, MD

    Durga Borkar, MD

    Durga Borkar, MD

    Assistant Professor of Ophthalmology

    Durga Borkar, MD is a board-certified, fellowship-trained adult vitreoretinal surgeon. She is an assistant professor of ophthalmology and assistant professor of population health sciences in Duke University’s Ophthalmology Department. She specializes in diabetic retinopathy, macular degeneration, retinal vascular occlusion, macular edema, macular holes, epiretinal membranes, vitreomacular traction, secondary intraocular lens placement, and complex retinal detachments, among others. Dr. Borkar’s academic interests include clinical-outcomes research using large administrative datasets. She has presented her work at numerous national and international retina meetings and is the recipient of several awards for excellence in research and clinical care, including the Heed Foundation Fellowship, the Society of Heed Fellows Award, and the AAO Advocacy Ambassador Award.
  • Eritrea Mussa

    Eritrea Mussa

    Eritrea Mussa

    Person living with Diabetes and Diabetic Macular Edema

    Eritrea Mussa has lived with type 1 diabetes for 23 years and has worked in the diabetes space as an advocate for most of her adult life. In 2020, a diabetic macular edema diagnosis taught her that there are many people living successfully with diabetes complications. She has always carried a strong love of travel and culture. Both of her parents are immigrants to America and a big part of her life has been spent traveling to visit family around the world. In her free time, Eritrea co-hosts DiabeticsDoingThings (, a podcast that focuses on telling the amazing stories of people living with diabetes. Eritrea enjoys reading, napping, and, above all, laughing as much as possible. She resides in Dallas with her dog.
  • Rishi P. Singh, MD

    Rishi P. Singh, MD

    Rishi P. Singh, MD

    Professor of Ophthalmology

    Rishi Singh, MD, is a staff surgeon at the Cleveland Clinic Florida, Professor of Ophthalmology at the Lerner College of Medicine, and President of Cleveland Clinic Martin Hospitals in Stuart, FL. He specializes in the treatment of medical and surgical retinal disease such as diabetic retinopathy and age-related macular degeneration. Dr. Singh has authored more than 200 peer reviewed publications and serves as the principal investigator of numerous clinical trials advancing the treatment of retinal disease. Dr. Singh is the former president on the Retina World Congress and is on the board of the American Society of Retina Specialists. Dr. Singh has been honored with several research recognitions such as the Alpha Omega Alpha Research Award.

CME Information

Global Logo PQH Logo

Patient-centered Approaches to Reduce Treatment Burden and Optimize Anatomical and Visual Outcomes in nAMD and DME

Jointly provided by Partners for Advancing Clinical Education (PACE) and PlatformQ Health Education, LLC, in collaboration with the American Macular Degeneration Foundation (AMDF)


Supported by an educational grant from Genentech, a member of the Roche Group.


This activity was released on February 28, 2024 and is valid until February 28, 2025. Requests for credit must be made no later than February 28, 2025.


The primary target audience for this activity includes Ophthalmology and retina specialist clinicians (MDs/DOs/NPs/PAs), optometrists, primary care clinicians, and diabetes educators.


Anti-VEGF agents initially approved for neovascular age-related macular degeneration (nAMD) and diabetic macular edema (DME) are limited by the need for frequent intravitreal injections and the potential for adverse events. New anti-angiogenesis agents and novel intravitreal delivery systems have the potential to reduce treatment burden and improve quality of life based on their proven efficacy and rapid and sustained impacts on anatomical and visual outcomes. Join an expert panel of ophthalmologists and a patient/caregiver to discuss the efficacy and safety of new treatment options that can help ophthalmologists and other clinicians to deliver optimal patient-centered care. The panel will also define the place of new and emerging treatment options in nAMD and DME, with the goal of providing rapid and vision-sustaining benefits.


After completing this activity, the participant should be better able to:
  • Describe patient- and non-patient-related barriers that prevent people with nAMD or DME from obtaining full benefit from anti-VEGF therapies.
  • Summarize evidence from clinical trials with newer agents on durable vision gains and retinal fluid reduction in nAMD and DME.
  • Review clinical trials and real-world evidence on individualized injection frequency and rapid efficacy with newer nAMD and DME treatments


ACPE Logo In support of improving patient care, this activity has been planned and implemented by Partners for Advancing Clinical Education (PACE) and PlatformQ Health Education, LLC. PACE is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.


PACE designates this enduring activity for a maximum of .75 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.


This activity should take approximately 45 minutes to complete.


In order to receive credit for this activity, the participant must (1) read the target audience, learning objectives, and disclosure statements, (2) complete the educational activity online, and (3) complete the post-test and activity evaluation. To receive AMA PRA Category 1 Credits™, participants must receive a score of 75% on the post-test.


Participants will need a computer with a recent version of Adobe Flash installed, as well as an internet connection sufficient for streaming media.


There is no fee for this educational activity.


PACE requires every individual in a position to control educational content to disclose all financial relationships with ineligible companies that have occurred within the past 24 months. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. All relevant financial relationships are mitigated according to PACE policies. The faculty reported the following relevant financial relationships or relationships to products or devices they have with ineligible companies related to the content of this educational activity:
Faculty Conflicts of Interest
Rishi P. Singh, MD Professor of Ophthalmology, Cleveland Clinic Lerner College of Medicine Staff Physician and Vice President/Chief Medical Officer of Cleveland Clinic Martin Hospitals Dr. Rishi Singh, faculty for this educational activity, has the following relevant financial relationships: • Consultant, Advisor, Speaker: Bausch and Lomb, Gyroscope, Allergan, Novartis, Regeneron, Genentech, Apellis, Alcon
Durga S. Borkar, MD, MMCi Assistant Professor of Ophthalmology Assistant Professor of Population Health Sciences Director of Clinical Data Science Duke University Eye Center Dr. Durga Borkar, faculty for this educational activity, has the following relevant financial relationships: • Consultant, Advisor, Speaker: Genentech, Glaukos, Iveric Bio, AbbVie/Allergan
Eritrea Mussa Patient panelist living with Diabetes and Diabetic Macular Edema Eritrea Mussa, patient panelist for this educational activity, has no relevant financial relationships.


This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.


Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.


Accreditation Support:

For additional information about the accreditation of this activity, please visit

Technical Support:

For any technical issues or issues with your CME Certificate, please contact ClinicalSeriesLive at 877-394-1306 or at